4 completed. 4 Phase 2.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 4 | Completed 4 |
Follow envafolimab: new trials by email Literature Review of envafolimab trials Research Report on envafolimab
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Study to Evaluate Safety, Tolerance and Efficacy of ASC22 Combined With ART in Subjects With HIV ASC22 1mg/kg, ASC22 2.5mg/kg, Antiretroviral Therapy - HIV-1-infection, HIV Infections | Phase 2 | Completed | Ascletis Pharmaceuticals Co., Ltd. | 19 | 2022-06-28 | 2024-11-25 |
| Preoperative Short-course Radiation Followed by Envafolimab Plus CAPEOX for MSS Locally Advanced Rectal Adenocarcinoma (PRECAM) Envafolimab, Oxaliplatin, Capecitabine - MSS Locally Advanced Rectal Adenocarcinoma | Phase 2 | Completed | Sir Run Run Shaw Hospital | 32 | 2022-04-07 | 2025-03-13 |
| Study on Therapeutic Effect of Combination of Envafolimab, Lenavatinib and TACE in Advanced HCC Patients Envafolimab, TACE, Lenvatinib - Advanced Hepatocellular Carcinoma | Phase 2 | Completed | Zhejiang University | 39 | 2022-03-14 | 2023-06-13 |
| Trial of Chidamide in Combination With Envafolimab in Patients With PD-1 Inhibitor Resistant Advanced NSCLC. Chidamide, Envafolimab - Non Small Cell Lung Cancer | Phase 2 | Completed | Chipscreen Biosciences, Ltd. | 34 | 2021-11-23 | 2024-08-07 |
Carcinoma, Non-Small-Cell Lung (1) · HIV Infections (1)
Ascletis Pharmaceuticals Co., Ltd. (1) · Chipscreen Biosciences, Ltd. (1) · Sir Run Run Shaw Hospital (1) · Zhejiang University (1)
China (4)
Li Zhang (1) · Sheng Dai, MD&PhD (1) · Tingbo Liang, PhD (1)